RxDoctor Payments Data

Jerome Grove, MD

Interventional Pain Medicine · Phoenix, AZNPI 1932153236

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by West Therapeutics Development, LLC at 47.5% of the total. Reporting peaked in 2019 at $14,394 and has fallen 95.1% since, to $708 in 2025.

$21,236in general payments, 2019–2025

Across 517 payments — averaging $41.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • West Therapeutics Development, LLC$10K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • AbbVie$1K
  • Collegium Pharmaceutical, Inc.$795
  • Medtronic$683
  • Nevro Corp.$637
  • plus $5K from 40 others

What the payments were for

  • Speaking & faculty fees$12,00057%
  • Travel & lodging$140%
  • Food & beverage$9,16843%
  • Education$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,236 in reported general payments places this provider in the 80th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$273,444
Medicare patients
529
Services billed
4,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl18$17,560
BotoxOnabotulinumtoxina11$13,109
Xtampza ErOxycodone Myristate24$11,918
Oxycodone Hcl267$5,739
Fentanyl46$5,211
Celecoxib41$5,170
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen140$3,591
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen118$3,520
Morphine Sulfate ErMorphine Sulfate127$2,984
Gabapentin139$1,895
Hydromorphone Hcl92$1,631
Naloxone Hcl21$1,407
Pregabalin51$1,023
Baclofen50$801
Diclofenac Sodium73$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$1,383$13,10911 claims
Collegium Pharmaceutical, Inc.Xtampza Er$795$11,91824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional pain medicine providers in Arizona.

Other interventional pain medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →